Day-time residual effects and motor activity after three benzodiazepine hypnotics. 1982

P Mattmann, and M Loepfe, and T Scheitlin, and D Schmidlin, and M Gerne, and I Strauch, and D Lehmann, and A A Borbély

The benzodiazepine hypnotics triazolam (T) (0.25, 0.5 and 1.0 mg), nitrazepam (N) (10 mg) and flunitrazepam (F) (2.0 mg) were investigated with respect to night-time effects and day-time residual effects, in healthy, young subjects. Drug or placebo was taken orally at home before bed-time. Tests for residual drug effects were administered in the laboratory throughout the following day. They included multiple sleep latency tests, the digit cancellation test, questionnaires, self-ratings and experimenter ratings. In addition, motor activity was recorded with a wrist-worn activity monitor during the drug-night, the day following drug intake, and the two subsequent nights. Residual effects consisted of reduced day-time motor activity (T 0.5, F 2.0), enhanced self-rated day-time sleepiness (T 1.0, F 2.0), increased experimenter-rated tiredness (T 0.5, F 2.0), and impaired performance in the digit cancellation test (F 2.0). Grogginess was a common symptom in the morning after flunitrazepam. All drugs reduced motor activity during sleep, and increased subjective depth and quietness of sleep. Increased motor activity in the second post-drug night was observed after triazolam 0.5 mg. The results indicate that a small dose of a short-acting benzodiazepine may be appropriate for promoting sleep without subsequent day-time residual sequelae.

UI MeSH Term Description Entries
D009043 Motor Activity Body movements of a human or an animal as a behavioral phenomenon. Activities, Motor,Activity, Motor,Motor Activities
D003071 Cognition Intellectual or mental process whereby an organism obtains knowledge. Cognitive Function,Cognitions,Cognitive Functions,Function, Cognitive,Functions, Cognitive
D004569 Electroencephalography Recording of electric currents developed in the brain by means of electrodes applied to the scalp, to the surface of the brain, or placed within the substance of the brain. EEG,Electroencephalogram,Electroencephalograms
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D001569 Benzodiazepines A group of two-ring heterocyclic compounds consisting of a benzene ring fused to a diazepine ring. Benzodiazepine,Benzodiazepine Compounds
D012890 Sleep A readily reversible suspension of sensorimotor interaction with the environment, usually associated with recumbency and immobility. Sleep Habits,Sleeping Habit,Sleeping Habits,Habit, Sleep,Habit, Sleeping,Habits, Sleep,Habits, Sleeping,Sleep Habit
D014151 Anti-Anxiety Agents Agents that alleviate ANXIETY, tension, and ANXIETY DISORDERS, promote sedation, and have a calming effect without affecting clarity of consciousness or neurologic conditions. ADRENERGIC BETA-ANTAGONISTS are commonly used in the symptomatic treatment of anxiety but are not included here. Anti-Anxiety Agent,Anti-Anxiety Drug,Anxiolytic,Anxiolytic Agent,Anxiolytic Agents,Tranquilizing Agents, Minor,Anti-Anxiety Drugs,Anti-Anxiety Effect,Anti-Anxiety Effects,Antianxiety Effect,Antianxiety Effects,Anxiolytic Effect,Anxiolytic Effects,Anxiolytics,Tranquillizing Agents, Minor,Agent, Anti-Anxiety,Agent, Anxiolytic,Agents, Anti-Anxiety,Agents, Anxiolytic,Agents, Minor Tranquilizing,Agents, Minor Tranquillizing,Anti Anxiety Agent,Anti Anxiety Agents,Anti Anxiety Drug,Anti Anxiety Drugs,Anti Anxiety Effect,Anti Anxiety Effects,Drug, Anti-Anxiety,Drugs, Anti-Anxiety,Effect, Anti-Anxiety,Effect, Antianxiety,Effect, Anxiolytic,Effects, Anti-Anxiety,Effects, Antianxiety,Effects, Anxiolytic,Minor Tranquilizing Agents,Minor Tranquillizing Agents

Related Publications

P Mattmann, and M Loepfe, and T Scheitlin, and D Schmidlin, and M Gerne, and I Strauch, and D Lehmann, and A A Borbély
April 1983, Pharmacology, biochemistry, and behavior,
P Mattmann, and M Loepfe, and T Scheitlin, and D Schmidlin, and M Gerne, and I Strauch, and D Lehmann, and A A Borbély
November 1977, La Clinica terapeutica,
P Mattmann, and M Loepfe, and T Scheitlin, and D Schmidlin, and M Gerne, and I Strauch, and D Lehmann, and A A Borbély
January 1972, Psychopharmacologia,
P Mattmann, and M Loepfe, and T Scheitlin, and D Schmidlin, and M Gerne, and I Strauch, and D Lehmann, and A A Borbély
January 1985, Drugs under experimental and clinical research,
P Mattmann, and M Loepfe, and T Scheitlin, and D Schmidlin, and M Gerne, and I Strauch, and D Lehmann, and A A Borbély
August 1990, Journal of clinical psychopharmacology,
P Mattmann, and M Loepfe, and T Scheitlin, and D Schmidlin, and M Gerne, and I Strauch, and D Lehmann, and A A Borbély
January 1985, Clinical neuropharmacology,
P Mattmann, and M Loepfe, and T Scheitlin, and D Schmidlin, and M Gerne, and I Strauch, and D Lehmann, and A A Borbély
September 1990, Hospital practice (Office ed.),
P Mattmann, and M Loepfe, and T Scheitlin, and D Schmidlin, and M Gerne, and I Strauch, and D Lehmann, and A A Borbély
June 2015, Nihon rinsho. Japanese journal of clinical medicine,
P Mattmann, and M Loepfe, and T Scheitlin, and D Schmidlin, and M Gerne, and I Strauch, and D Lehmann, and A A Borbély
January 1994, Acta psychiatrica Belgica,
P Mattmann, and M Loepfe, and T Scheitlin, and D Schmidlin, and M Gerne, and I Strauch, and D Lehmann, and A A Borbély
August 1985, Accident; analysis and prevention,
Copied contents to your clipboard!